Over the past few decades, bladder cancer standard of care has not changed, with platinum-based chemotherapy and BCG as the core pillars of care. The last 12 months have seen two new regimens approved for frontline locally advanced / metastatic urothelial and one new treatment approved for BCG-unresponsive CIS NMIBC, significantly improving survival outcomes for patients. Many other clinical programs have continued progressing, ushering in a new wave of novel, targeted, and potentially more tolerable bladder cancer treatments. 

In this Bladder Cancer Awareness Month special episode of Axiom Catalyst, Andrew Kassin and Kiana Ziadkhanpour interview Dr. Petros Grivas, a thought-leading GU Medical Oncologist of University of Washington and Fred Hutchinson Cancer Center, to discuss innovative bladder cancer treatments, changing treatment practices, and patient risk factors. 

We are honored to continue spreading awareness for bladder cancer to help patients around the world! #BladderCancerAwarenessMonth2024 #AxiomThinkTank

Severe care disparities, barriers to diagnosis, harrowing patient stories, historically low survival… and yet… enduring hope for women worldwide.
While significant progress has been made to address needs of women with gynecologic cancers, and the last 12 month have seen huge strides in advancing standards of care, key challenges remain including the inclusivity of clinical studies, asymmetric engagement and awareness across communities, and limited ability to tailor therapies, especially in later lines as care options dry up.
In this this Gynecologic Cancer Awareness Month special episode of Axiom Catalyst, Dan Simpson, Carlie Darefsky, Harish Venkatesan and Flannery Nania talk through the challenges and hope for patients, as we look to the healthcare industry to raise the bar on health standards.
This short podcast complements the specific infographics the Axiom team developed to highlight specific needs and challenges in cervical, ovarian and endometrial cancers respectively.

Let’s keep raising awareness and saving lives! 🌸💪

#CervicalCancer #OverianCancer #EndometrialCancer #HealthcareAdvocacy #TogetherAgainstCancer #GynecologicCancer #GynAwarenessMonth2023 #AxiomThinkTank 

In collaboration with Nick Gherardin from University of Melbourne, and Hafiz, Anne has recently co-authored a review article in Frontiers in Oncology about the novel clinical strategies companies are taking to bring gamma delta-inspired therapies to the clinic.

Anne Cherry joins the Axiom Catalyst with Mahim Misra to discuss her paper and some of the exciting developments in gamma delta inspired therapies.

Dr. John Tsai, former President of Global Drug Development and CMO of Novartis, joins the Axiom Table with Hafiz Sikder. The conversation spans the changing landscape of Immuno-Oncology, AI, and the impact of COVID-19.

Michelle Werner, CEO Partner of Flagship Pioneering and CEO of Alltrna, joins Hafiz Sikder to discuss her work and role at Alltrna as well as her personal investment in the field. She dives deep into the impact of tRNA on drug development, premature stop codons, and her drive to do more for rare disease.

Join us as we discuss the latest developments in RCC coming out of ESMO22. In this episode, we recap the impact of 3 failed checkpoint-based regimen trials within the (neo)adjuvant setting and the first positive triplet data for advanced RCC.

Join us as Rohan and Andrew discuss key takeaways from an impactful ESMO22 in NSCLC. In this episode, we recap the first Phase III data for a KRASG12C inhibitor, long-term follow-up from checkpoint-based regimens, and the first ADC approval in lung.

Dr. Hope Rugo, University of California at San Francisco, joins Hafiz Sikder for an engaging discussion on the world of Breast Cancer. The discussion ranges from key ESMO data, the future of care, and healthcare disparities.

Join in this week as we review key data-set from ESMO as well as a deep dive into RCC, lung and pan-tumor discussions. Join in the discussion with your POV, comments, and questions.

Axiom Catalyst is live from Gustave Roussy! Hafiz Sikder joins Dr. Barlesi and the leading cancer treatment team in Villejuif, France for a discussion on the future of oncology.

Live from the congress floor! Join Mahim Misra and Maressa Cumbermack for part 2 of our ASCO Snacks series, a quick download on the day’s most exciting events. Axiom Catalyst will record live at the 2022 American Society of Clinical Oncology’s Annual Meeting in Chicago.

Live from the congress floor! Join Mahim Misra, Charlotte Caine, and Maressa Cumbermack for part 1 of our ASCO Snacks series, a quick download on the day’s most exciting events. Axiom Catalyst will record live at the 2022 American Society of Clinical Oncology’s Annual Meeting in Chicago.

Dr. Han Phan is a member of the Pediatric Advisory Board at the FDA, and the Director of Rare Disease Research center. She joins the Axiom Table with Akash Bhattacharjee. This discussion goes though her experience with diagnosing and treating Duchenne patients, challenges faced by manufacturers in this space, and one of the most eagerly anticipated news of the year in Pharma. 

Vicky Kuo, MS, and Rohan Gidvani, PhD, join Hafiz and Mahim this week to discuss cell and gene therapy before ASCO 2022. Tune in for insights on challenges and emerging technologies from the Axiom Table.

Dr. Hossein Borghaei, Fox Chase Cancer Center, joins Hafiz and Mahim today to discuss updates in TIGIT, Immunotherapy, and more.

On Wednesday April 27, ASCO released 2800+ abstract titles spanning all major tumor types. On today’s podcast, we will give you a glimpse into some of the impactful abstracts that will be presented at ASCO in June. Topics will range from practice changing Phase III results from ADCs to emerging modalities like CAR-engineered allogeneic γδ T cells.

Subscribe to the Axiom Catalyst! We will meet weekly to give you timely, holistic updates in life sciences.

May is ALS Awareness Month and this year Axiom is marking it with a dedicated podcast to help raise awareness about amyotrophic lateral sclerosis (ALS) also known as motor neuron disease. ALS is fatal with the average life expectancy after diagnosis being two to five years, although some patients may live for years or decades. There is still no known cure for ALS and current treatment options primarily target symptoms to improve quality of life, rather than stopping the disease progression.

In this episode of Axiom Catalyst, Anna Graca is speaking with Dr Tim Williams from the Newcastle MND Care and Research Centre about how this devastating disease affects each individual differently and tremendous efforts of treating physicians and care coordinators to provide a personalised support to these patients and their families. 

There are~ 30 million people in Europe alone living with a rare condition, of which 75% have neurological symptoms. While significant progress has been made to address needs of these patients, key challenges remain including the scarcity of the expertise and fragmentation of research efforts that translate into delayed diagnosis, few disease modifying therapies, and difficulty in accessing adequate care.

In this episode of Axiom Catalyst, we invited Frédéric Destrebecq, the Executive Director of the European Brain Foundation and European Brain Council to discuss how coordinated efforts between patient organisations, research and clinical networks, drug innovators and policy makers, can tackle these challenges and reduce the high burden posed by rare neurological disorders in Europe and beyond.

While significant therapeutic advances are underway for inherited blood disorders such as sickle cell disease, hemophilia and β-thalassemia, key challenges remain for the commercialization of these therapies, as well as disparities in access to these treatments and level of care received by patients.

In this episode of Axiom Catalyst, we invited John James, CEO of Sickle Cell Society to discuss the impact of sickle celldisease on day-to-day lives of patients living in the UK, as well as current challenges in their clinical journey. We also explore the outreach work done by the Sickle Cell Society including key local initiatives such as the Hackney engagement project, and the translatory impact of their patient support work.

Join Nicole, Kiana, and Madelyn's discussion on updates seen at ASCO GU 2023. We analyze some of the most anticipated read outs in RCC, bladder, and prostate cancers and consider what this data means for physicians and patients.

Join Justin, Rodrigo and Eriko’s discussion on bispecific antibody and CAR-T therapies. These innovative options are increasingly becoming available in late-line treatments for heme cancers. In this episode, we cover the advantages and disadvantages of bispecific and CAR-T treatments, emerging CRS considerations, as well as future directions for both modalities in how they pertain to myeloma and lymphoma treatment.

Join Mahim, Samy, & Aman on exciting updates following the ASCO Gastrointestinal Cancers Symposium data readouts as we start 2023 with some exciting updates. In this episode, we share the latest news following recent approvals, 3-year data readouts, and developments in Gastrointestinal, Pancreatic, Colorectal, Hepatocellular Carcinoma, and Biliary Tract Cancer.

Join Mahim and Allegra's discussions on the latest developments in gynecologic oncology as we wrap up 2022 and enter into the new year. In this episode, we recap the impact of antibody drug-conjugate approvals in cervical and ovarian cancers, new PARP inhibitor data in ovarian cancer, and exciting immunotherapy results in frontline endometrial cancer.

What does it take to navigate through the complex question of when and with whom to partner for a companion diagnostic?

Join us in yet another invigorating episode at #AxiomCatalystPodcast where Anne Cherry hosts top industry experts, Kara O'Brien and Tricia Carrigan to share invaluable insights on:

✅ Choosing the right technology

✅ Deciding between in-house development and partnerships

✅ Timing your collaborations strategically

✅ Selecting the ideal diagnostic partner

Subscribe now so you don't miss a beat from the #AxiomTable

#CompanionDiagnostics #PrecisionMedicine #PharmaInnovation #PharmaStrategy

Go-to-Market Strategies: In this dynamic panel discussion moderated by the Managing Principal of Axiom Healthcare Strategies, experts dive into innovative strategies that are reshaping how pharma companies bring new therapies to market. From leveraging advanced data analytics to navigating regulatory pathways, the conversation covers key approaches to speed up launches and maximize impact for patients in oncology and rare diseases.

To learn more about how we galvanize innovative product launches across oncology and rare diseases, reach out to our Managing Director, Jon Yoder, at jy@axiomhcs.com

Catch the full conversation here: https://www.youtube.com/watch?v=_-oWLf_YeJo

#HealthcareInnovation #ProductLaunch #LifeSciences #AxiomSummit #AxiomThinkTank

Industry at a Crossroads – Presented by Jon Yoder, Managing Director of Axiom Healthcare Strategies, this insightful session explores the pivotal challenges and opportunities shaping the future of the healthcare industry. Don’t miss these strategic perspectives on where the industry is headed.

To learn more about the future of the biotech industry and its investor ecosystem, reach out to Jon at jy@axiomhcs.com

Watch the full session here: https://www.youtube.com/watch?v=j9ry7pvb_1I

#HealthcareIndustry #Strategy #AxiomSummit #Innovation

Best Foot Forward: Optimizing Clinical Trials during Today's Crossroads – Moderated by Giovanni Abbadessa of ModeX, this insightful panel features Lisa Mahnke of Nerviano Medical Sciences and Christiana Bardon of MPM. Discover how these leaders are optimizing clinical trials and evaluating asset strength in today's rapidly evolving healthcare landscape.

To learn more about how we can help you develop your pre-clinical platform and prioritize effective clinical development plans, reach out to our Chief of Strategy, Anne Cherry, at ac@axiomhcs.com

Watch the full discussion here: https://www.youtube.com/watch?v=pKMls_9UV80

#ClinicalTrials #HealthcareInnovation #AxiomSummit #MedicalResearch

Crossroads Between Oncology & Rare Diseases – Moderated by Anne Cherry, this panel features Michelle Werner from Alltrna. Explore the critical intersections of oncology and rare diseases, and how insights from one world can provide insight to the other.

Watch the full panel here: https://www.youtube.com/watch?v=1e6Ozg2_YL0

To learn more about our work supporting companies driving innovation across oncology and rare disease, reach out to Anne at ac@axiomhcs.com

#Oncology #RareDiseases #HealthcareInnovation #AxiomSummit

Reimagining Clinical Trials – A thought-provoking panel moderated by the Managing Principal of Axiom Healthcare Strategies, featuring exertise among physicians and industry leaders: Hossein Borghaei, Corey Langer, Shruti Agrawal, Robert LaCaze, Alan Bash, and Nicholas Davies. Explore innovative approaches transforming traditional trial models.

To learn more about our work supporting innovation in study designs, reach out to our Chief of Strategy, Anne Cherry, at ac@axiomhcs.com

Watch the full panel here: https://youtu.be/Jf_4J9YZLI4?feature=shared

#ClinicalTrials #FutureOfClinicalTrials #InnovatingResearch #ClinicalTrialsReimagined #AxiomSummit

CEO and Founder Spotlight – A dynamic panel moderated by the Managing Principal of Axiom Healthcare Strategies, featuring industry leaders, Alan Bash, Lea Hachigian, Robert LaCaze, and Michelle Werner. Dive into their journeys, insights, and visions for the future of healthcare.

To learn more about how Axiom supports biotech leaders and their organizations to excel, reach out to our Chief of Strategy, Anne Cherry, at ac@axiomhcs.com

Watch the full panel discussion here: https://www.youtube.com/watch?v=sdfYENHWR28

#Leadership #HealthcareInnovation #AxiomSummit #Entrepreneurship

Anne Cherry, Chief of Strategy at Axiom Healthcare Strategies, dives deep into identifying gaps and opportunities across the product development lifecycle. Learn how strategic insights are transforming patient outcomes and driving innovation. #AxiomCrossroads #BeBio #AxiomThinkTank

Partnering for Innovation – A powerful discussion led by Paul Biondi of Flagship Pioneering at the Axiom Crossroads Summit! Explore insights on how groundbreaking collaborations are shaping the future of healthcare and driving innovation. #AxiomCrossroads #BeBio #AxiomThinkTank

From the first new treatment in locally advanced cervical cancer in over a decade to buzz around exciting new drugs in development for ovarian and endometrial cancer, there have been many advances made in gynecologic cancer treatment in the past 12 months. 

In this Gynecologic Cancer Awareness Month special episode of Axiom Catalyst, Carlie Darefsky, Harish Venkatesan, Flannery Nania, and Luke Anderson talk through the challenges and hope for patients of gynecologic cancers. 

This podcast complements the infographics the Axiom team developed to highlight specific needs and challenges in cervical, ovarian, and endometrial cancers.

#GynecologicCancer #GynAwarenessMonth2024 #AxiomThinkTank

In this episode of the Axiom Catalyst Life Sciences Podcast, Jai Bains speaks with Dr. Gayathri Swaminath, VP of Cardiovascular at Pioneering Medicines, about the evolving role of pre-emptive medicine in cardiometabolic renal disease, with a focus on chronic kidney disease. From redefining early intervention to exploring the role of biomarkers, and multi-omics, this conversation dives into the science, system barriers, and future outlook for tackling CKD earlier and more effectively.

Listen in to learn more!

Chiranth Achar discussed the rare disease landscape in India with Prasanna Shirol, Co-founder & Director of the Organization for Rare Diseases India.

The ORDI would like to make listeners aware of the significant work done by them in aid of rare disease patient in India. This includes India’s First Rare Disease Helpline: (+91) 8892 555 000, the Savemylife patient support program, Racefor7 a symbolic 7,000 meter race to raise rare disease awareness and drive outreach across India to connect all stakeholders, and significant collaboration with international bodies such as Rare Diseases International.

Dan Simpson connected with Prof. Dave Pearce, Chair of the International Rare Diseases Research Consortium (IRDiRC) and professor of pediatric rare diseases. Prof. Pearce speaks passionately about the needs of rare disease patients around the world, and how the IRDiRC brings together funding agencies, companies, patient advocate groups, and other organization from approximately 80 countries to address patient care through a number of core initiatives.

The IRDiRC is a global collaborative initiative launched in 2011 by the European Commission and the U.S. National Institutes of Health to tackle rare diseases through research and accomplish the vision to enable all people living with a rare disease to receive an accurate diagnosis, care, and available therapy within one year of coming to medical attention. Dr. Pearce is an internationally recognized leader in a number of areas. He has published over 100 research papers on Batten disease, founded an international registry for rare diseases known as the Coordination of Rare Diseases at Sanford (CoRDS), and has served on numerous NIH review committees, rare disease advisory boards and has organized rare disease workshops. 

Marissa McPhillips met Michelle, in her capacity as CEO of Alltrna, for a constructive conversation around the critical role industry plays in developing innovative treatments for rare disease. We heard how it takes an environment that supports innovation, with incentives, novel clinical trial designs, and other enabling regulations – with Michelle urging the rare disease community to continue to push for these things.

For more information about Alltrna and how they are scaling rare disease drug development by pioneering tRNA medicines to treat Stop Codon Disease, check out their LinkedIn page, YouTube channel, and X account (formerly Twitter).

Seona Lee and Dr Brandsema, pediatric neurologist at CHOP, discuss his firsthand specialist physician’s experience in treating rare disease patients – including the challenges, progress and hope for 2025. Listen in for some inspiring patient stories.

Check out the work CHOP is doing to improve the lives of patients with Duchenne’s (DMD) here.

Asia’s oncology landscape is changing fast.

In this latest Axiom Catalyst episode, the #AxiomThinkTank India team and top regional experts, including 𝗗𝗿. 𝗞𝗼𝗵𝗲𝗶 𝗦𝗵𝗶𝘁𝗮𝗿𝗮, who focuses on innovative therapies for gastrointestinal cancers, and Dr. Vanita Noronha, who specializes in enhancing treatment options for geriatric oncology patients, dig into the most exciting #ESMO2025 breakthroughs - from novel immunotherapies to ADCs - and explore how they could reshape treatment access and standards across Asia.

#ESMO25 #OncologyInsights #AsiaOncology #OncologyInAsia